HMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine

The tau protein aggregation inhibitor hydromethylthionine mesylate (HMTM) was shown recently to have concentration-dependent pharmacological activity in delaying cognitive decline and brain atrophy in phase 3 Alzheimer’s disease (AD) clinical trials; the activity was reduced in patients receiving sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Renato X., Melis, Valeria, Goatman, Elizabeth A., Leith, Michael, Baddeley, Thomas C., Storey, John M. D., Riedel, Gernot, Wischik, Claude M., Harrington, Charles R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029156/
https://www.ncbi.nlm.nih.gov/pubmed/35453617
http://dx.doi.org/10.3390/biomedicines10040867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029156/
https://www.ncbi.nlm.nih.gov/pubmed/35453617
http://dx.doi.org/10.3390/biomedicines10040867

Ejemplares similares